S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Elon Did It Again: This Could be Bigger than Tesla (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Top Analyst Exposes Imminent Crisis Hurtling Towards America (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Elon Did It Again: This Could be Bigger than Tesla (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Top Analyst Exposes Imminent Crisis Hurtling Towards America (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Elon Did It Again: This Could be Bigger than Tesla (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Top Analyst Exposes Imminent Crisis Hurtling Towards America (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Elon Did It Again: This Could be Bigger than Tesla (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Top Analyst Exposes Imminent Crisis Hurtling Towards America (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:BFRI

Biofrontera (BFRI) Stock Forecast, Price & News

$8.49
-0.25 (-2.86%)
(As of 10/3/2023 ET)
Compare
Today's Range
$8.48
$8.82
50-Day Range
$8.09
$12.34
52-Week Range
$7.41
$25.80
Volume
2,670 shs
Average Volume
11,478 shs
Market Capitalization
$11.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Biofrontera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.0% Upside
$18.00 Price Target
Short Interest
Healthy
2.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($15.78) to ($6.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

531st out of 966 stocks

Pharmaceutical Preparations Industry

236th out of 434 stocks


BFRI stock logo

About Biofrontera (NASDAQ:BFRI) Stock

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.

BFRI Price History

BFRI Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Earnings Outlook For Biofrontera
Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Biofrontera Inc. Announces Resignation of CEO
Biofrontera Inc. Common Stock (BFRI)
See More Headlines
Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

BFRI Company Calendar

Last Earnings
8/11/2023
Today
10/03/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BFRI
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+112.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-640,000.00
Pretax Margin
-77.96%

Debt

Sales & Book Value

Annual Sales
$28.67 million
Book Value
$17.89 per share

Miscellaneous

Free Float
1,359,000
Market Cap
$11.63 million
Optionable
Not Optionable
Beta
1.09
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Hermann Luebbert Ph.D. (Age 67)
    Chairman, CEO & Pres
    Comp: $476.36k
  • Mr. Eugene Fredrick Leffler III (Age 39)
    Chief Financial Officer
    Comp: $316.32k
  • Ms. Erica F. Gates CPA
    M.B.A., Sr. Director of Fin. & Principal Accounting Officer
  • Mr. Jon Lyons M.B.A.
    Ph.D., VP of Scientific & Medical Affairs
  • Ms. Alycia Torres
    VP of Admin.
  • Mr. Daniel Hakansson J.D.
    Gen. Counsel & Head of Compliance
  • Ms. Samantha Widdicombe
    Sr. Director of Strategic Accounts & Communications
  • Mr. Mark Baldyga
    VP of & Marketing
  • Mr. Anthony Takazawa
    Exec. Officer













BFRI Stock - Frequently Asked Questions

Should I buy or sell Biofrontera stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BFRI shares.
View BFRI analyst ratings
or view top-rated stocks.

What is Biofrontera's stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price objectives for Biofrontera's shares. Their BFRI share price forecasts range from $18.00 to $18.00. On average, they expect the company's share price to reach $18.00 in the next year. This suggests a possible upside of 112.0% from the stock's current price.
View analysts price targets for BFRI
or view top-rated stocks among Wall Street analysts.

How have BFRI shares performed in 2023?

Biofrontera's stock was trading at $18.3320 at the beginning of the year. Since then, BFRI stock has decreased by 53.7% and is now trading at $8.49.
View the best growth stocks for 2023 here
.

Are investors shorting Biofrontera?

Biofrontera saw a increase in short interest in September. As of September 15th, there was short interest totaling 21,000 shares, an increase of 9.4% from the August 31st total of 19,200 shares. Based on an average daily volume of 16,600 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the company's stock are sold short.
View Biofrontera's Short Interest
.

When is Biofrontera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our BFRI earnings forecast
.

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) released its quarterly earnings results on Friday, August, 11th. The company reported ($6.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.14) by $1.00. The business earned $5.85 million during the quarter, compared to analyst estimates of $5.86 million. Biofrontera had a negative trailing twelve-month return on equity of 126.98% and a negative net margin of 78.03%.

When did Biofrontera's stock split?

Shares of Biofrontera reverse split on the morning of Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Biofrontera issued on next quarter's earnings?

Biofrontera updated its FY 2023 earnings guidance on Sunday, September, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $35.84M-.

When did Biofrontera IPO?

(BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRI."

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biofrontera's stock price today?

One share of BFRI stock can currently be purchased for approximately $8.49.

How much money does Biofrontera make?

Biofrontera (NASDAQ:BFRI) has a market capitalization of $11.63 million and generates $28.67 million in revenue each year. The company earns $-640,000.00 in net income (profit) each year or ($17.83) on an earnings per share basis.

How can I contact Biofrontera?

The official website for the company is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at us-ir@biofrontera.com.

This page (NASDAQ:BFRI) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -